病原生物学——叶飞

　　一、个人简介

　　叶飞，男，2015年博士毕业于北京协和医学院，后一直在中国疾病预防控制中心病毒病所从事疾控和科研等相关工作。

　　曾作为队员参与“援助非洲，抗击埃博拉”援外活动，在西非塞拉利昂工作半年。以冠状病毒和痘病毒为研究重心，侧重基于反向遗传学、小动物活体成像等技术，开展病毒的病原学、致病机理和抗病毒药物等研究。研究工作得到国家自然科学基金、北京市自然科学基金、国家重点研发计划等项目的支持。发表了包括Nature、Cell Host Microbe、STTT、NC等杂志在内的相关论文30余篇，其中以第一作者(含共一)发表SCI论文20篇。

　　二、主要研究方向

　　冠状病毒和痘病毒的病原学、抗病毒药物筛选、病原微生物基因组测序。

　　三、代表性论文、成果

　　1.Ye F, Huang B, Zhao L, Deng Y, Ren J, Tan W.2022. Novaferon Effectively Inhibits Ancestral SARS-CoV-2 and Omicron Variant in Vitro, 2022. China CDC Wkly 4:509-512.

　　2.Lai X, Yu Y, Xian W, Ye F, Ju X, Luo Y, Dong H, Zhou YH, Tan W, Zhuang H, Li T, Liu X, Ding Q, Xiang K.2022. Identified human breast milk compositions effectively inhibit SARS-CoV-2 and variants infection and replication. iScience 25:104136. (Co-first author)

　　3.Yao Y, Ye F, Li K, Xu P, Tan W, Feng Q, Rao S.2021. Genome and epigenome editing identify CCR9 and SLC6A20 as target genes at the 3p21.31 locus associated with severe COVID-19. Signal Transduct Target Ther 6:85. (Co-first author)

　　4.Xi J, Ma C, Wei Z, Yin B, Zhao S, Quan W, Yang J, Yuan J, Qiang B, Ye F, Peng X.2021. A single mutation in the cis-acting replication element identified within the EV-A71 2C-coding region causes defects in virus production in cell culture. Emerg Microbes Infect doi:10.1080/22221751.2021.1977590:1-28. (Co-corresponding author)

　　5.Sun Q, Ye F, Liang H, Liu H, Li C, Lu R, Huang B, Zhao L, Tan W, Lai L.2021. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther 6:212. (Co-first author)

　　6.Bai Y, Ye F, Feng Y, Liao H, Song H, Qi J, Gao GF, Tan W, Fu L, Shi Y.2021. Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir. Signal Transduction and Targeted Therapy 6. (Co-first author)

　　7.Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D.2020. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis doi:10.1093/cid/ciaa237. (Co-first author)

　　8.Fu L, Ye F, Feng Y, Yu F, Wang Q, Wu Y, Zhao C, Sun H, Huang B, Niu P, Song H, Shi Y, Li X, Tan W, Qi J, Gao GF.2020. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat Commun 11:4417. (Co-first author)

　　9.Ye F, Song J, Zhao L, Zhang Y, Xia L, Zhu L, Kamara IL, Ren J, Wang W, Tian H, Wu G, Tan W.2019. Molecular Evidence of Human Monkeypox Virus Infection, Sierra Leone. Emerg Infect Dis 25:1220-1222.

　　10.Xi J, Ye F, Wang G, Han W, Wei Z, Yin B, Yuan J, Qiang B, Peng X.2019. Polypyrimidine Tract-Binding Protein Regulates Enterovirus 71 Translation Through Interaction with the Internal Ribosomal Entry Site. Virol Sin 34:66-77. (Co-first author)